Pertuzumab Archives - Medical Conferences

Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer

Presented By

Dr Eugene Ahn, Cancer Treatment Centers of America, IL, USA

Trial

Phase 2, TAPUR

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:45

T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Presented By

Dr Fabrice André, Institut Gustave Roussy, Paris, France

Trial

Phase 2, DESTINY-Breast07

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 10:55

T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported

Presented By

Prof. N. Harbeck, University of Munich, Germany

Trial

Phase 3, KAITLIN

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 09:40

Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer

Presented By

Dr Javier Cortés, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 2, PHERGAIN

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 08:50

Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer

Trial

APHINITY

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:13

HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

Trial

Phase 2, DESTINY-Breast01

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 22:54

Subcutaneous pertuzumab + trastuzumab non-inferior to the IV combination

Trial

Phase 3, FeDeriCa

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 21:44

Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer

Presented By

Dr Ian E. Krop, Dana-Farber Cancer Institute, USA

Trial

Phase 3, APHINITY

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 14:00

Extrapolating data from clinical trials as we treat patients in real life

Presented By

Prof. Sharon Giordano, MD Anderson, Houston, USA

Trial

APHINITY, KATHERINE, ExteNET

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 23:44

Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA

Trial

KATHERINE, CREATE-X

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 16:29

Adjuvant Her2-targeted therapy

Trial

APHINITY

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 13:35

site created by:

© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy

HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com